david: new developments on the vaccine front, pfizer saying its covid-19 vaccine candidate could be ready for regulatory approval as early as october. steve herrigan has all the details hi, steve. >> reporter: david very positive vaccine news, pfizer coming out with the announcement now confirming that its top vaccine could be ready for regulatory approval as early as october. this means the vaccine could be used ready for use inside the u.s. as early as november, and potentially could have an effect on the presidential election. the confirmation of that october goal by pfizer really makes this one of the fastest-moving vaccines in the world, one of the big pluses is so far, the lack of side effects in phase i of the testing fewer than 20% suffered mild fevers from the use of this vaccine. pfizer and bion tech last month reached a $2 billion agreement with the federal government to produce more than initially 100 million doses of the vaccine in the u.s.. in the meantime the cdc is expressing concern about the start of flu season coming

so as far as pfizer abuses going to syria there was tremendous pfizer abuse it's amazing that it's taken this long and everyone knows it it's been proven very substantially not only pfizer abuse changing documents and putting documents in front of the pfizer court and courts that are a disgrace well that they could have done it and the fact is we caught. joe biden president obama the whole group you can look at brennan and call me and clapper the whole group we caught him spying on our campaign this was an illegal act. like no other illegal act this was treason this was at the highest level of treason and obama and biden got caught spying on my campaign using intelligence agencies of the united states government to do it both before and after the election so before the election then after i won they continued it's totally illegal activity and now we just have. to see what's happening but as far as. kemal is concerned she's a big tax raiser she's a big. slasher of phones for our military and she's got a lot of difficult things that she's going to have to explain plus she was very very nas

>> sleeping with the pfizers what do we think about pfizer?izer, you have to like it for more than just a play on the vaccine. you've got as ttrazeneca. there are certain things i like about pfizer valuation and the fact they are spitting off or getting rid of their -- and cause excuse me, da blank." blank. what i'll say is october, right? you're kind of in the sweet spot around route time where your value starts to erode so i would be looking to probably roll that position if you don't get a stock move in short order. >> carter worth, we go to you. the majority of analysts here on cnbc's data sheet have a hold rating on the stock and also now down about 4% on a year to date basis. is this a sock ytock you want tt involved with? >> it goes in the bucket of large cap laggered that has the potential to catch up. and so 18% off the all-time high, s&p making all-time highs. this is the thing if you have an extended name, let's trim that and double back and find something like this, like a starbucks, like a faiz pfizer t lagged and has catchup pote

it is like the face of biotech of 2000 and 2020 i'm sure the pfizer people scratch their heads and pfizer is a 4% yield. as a portfolio manager, i would headache th make this call although definitely not the best or most representati representative i'd go there with others i write about all the time there is raytheon for honey well this is not having to do with raytheon it's so straightforward it's basically housekeeping when the old united technologies flight, they merged businesses a carrier of the climate control. it was diversified the new raytheon is similar to another dow jones boeing meanwhile, honeywell looks prebreakup they have aerospace and performance materials, safety and productivity solutions these are highly engineered, that's the keyword, businesses, hon honeywell, they have a vaccine packaging more practical than glass viles. the heating and air conditioning systems are packed with software and growing at a 20% clip. 300% increase in orders and a backlog of 140%. they have the best mass franchise for anybody worried about covid. listen to what jp morgan, the best industr

three good names here. >> pfizer is one of the hot names on the vaccine side, coming back but still well below where it was a couple of years ago. >> i don't think pfizer is in play for a vaccine necessarily you have some potential tailwind with that. it's too cheap and it's clearly lagged some of its bigger competitors, for example eli lilly. i like the caterpillar one that 135 level seems to be a line in the sand i think you can get back up to that 150 level we saw back in late january, early february. >> wow bullish call there for caterpillar from mr. guy adami. >>> coming up, call it a big box blowout. a pair of retailers reporting rock solid results why didn't their stocks respond a little more? >>> later on as tiktok takeover talks heat up, we're going to play a game of matchmaker. look here, it's your very own all-in-one entertainment experience: xfinity x1. it's the easiest way to watch live tv and all your favorite streaming apps. plus, x1 also includes peacock premium at no extra cost. this baby is the total package. it streams exclusive originals, the full peacock movie l

pfizer has been and pfizer has been working on a potential vaccine for coronavirus.zon is in talks to speed up the service. there are reports in "the washington journal" that it's been talking to simon property group about repurposing j.c. penney's as fulfillment centers. that would mean having less traffic through the mall, which is essential to doing business but it would get a reliable tenant and finding paying tenants is challenging at this stage. so amazon might be a decent tenant for simon properties. but we're not hearing anything affirmative right now. >> you just talked about businesses collapsing because of the coronavirus crisis. you're also seeing millennials hit hard by the economic collapse. what can you tell us about this? >> they're bouncing from one crisis to the next. particularly for this demographic. if you think about it, they came into the workforce around the time of the last financial crisis so struggling to attain jobs and the move up the career ladder many still hanging onto debts, including student loans, personal loans but you're seeing mo

. >>> welcome back biontech and pfizer moving higher today the company is announcing they could see a regulatory review a soon as october. this after johnson & johnson announced plans to launch a late stage vaccine trial with up to 60,000 participants in september. joining us now for more is former fda commissioner dr. scott gottlieb

. >>> we have a market flash in pfizer and bristol myers >> both of those shares are higher after hours as the company won a patent ruling on their blood thinner drug eliquis. you're seeing bristol up almost 5% on this bristol does have the majority on this drug it brings in more than $7 billion a year pfizer up.6% on this ruling now. >> certainly in recent days there have been many other reasons for owning pfizer, namely the vaccine that could be coming to market. >> it hasn't been a great performer but i think pfizer is just too cheap as well bristol myers has been an underperformer in order for that to break out, i think it needs to close above 65 with this news we're probably within a couple dollars of that. i think pfizer out of the two is probably the better book eli lilly has come off a little bit since its all-time high. the stock has been a monster i think eli lilly sets up the beth of t bestof the three. >> breaking news out of washington, d.c. >> stimulus talks have broken for this evening house speaker nancy pelosi telling reporters she's confident there will be a light at t

hawley: let me remind you of what the pfizer court said. the fbi's handling of the carter page applications was antithetical to the heightened duty of candor owed to the court. the frequency with ritz representations made by fbi personnel turned out to be unsupported or contradicted by information in their possession and with which they withheld information detrimental to their case, calls into question whether information contained in other f young applications is reliable. are you still look the view that these applications were not a close call at all and you would do the same thing now? these were appropriate steps? do you stand by that? miss yates: yes, senator. if you put my testimony in context, i was referring to the decision i made at the time. based on the factual information presented to me. sen. hawley: you for a passive party in this? you are telling us now, you did read the applications but you were also duped by the fbi and for that reason you signed off on misleading applications that a fisa court said were so bad and mislea

now, let's get straight to the bloomberg business flash we start with pfizer.he covid vaccine they are working on is on track for regulatory exchange next october. it would make it one of the fastest moving vaccines in the world. they previously secured a deal to supply 100 million doses to the u.s. has a stay in california. a judge has allowed to challenge a previous order complying with the state law. the state wants them to treat workers as employees, a move that would upend their business model. pay $1.6 agreed to billion over is now withdrawn essure device. it caused bleeding and failed to prevent pregnancy. 39,000 lawsuits, considerably more than bayer paid to the company that actually made the device.

government made with, you'll have to remind me i think it was pfizer. are these bets that these companies are be first to market or are they really rather more like an option or a hedge on those companies. >> probably all of the above you're exactly right the government did make that deal with pfizer to pay if it's approved or gets authorization it doesn't pay anything unless the vaccines available governments around the world are probably trying to make bets on which vaccines will be available. which will work the best all of this going into the considerations of where they are trying the place purchase orders right now. >> all right,sir thank you very much. >>> let's go to seema mody for "trading nation. >> one of the hottest stay at home stocks said to report earnings back at the bell. zoom video major beneficiary of employees shifting from work from home set ups during the pandemic. analysts expecting the company to increase sales by more than 240% in the three months ending in july. michael, there was the note from justice of the peace n jpmorgan s

to learn more, visit paycom.com >>> take pfizer, the payments company more behind the scenes from theancial tech place we focus on they operate on the plumbing for financial institutions and merchants accepting credit card payments maybe there is a ton of consolidation including the merging in a deal that should produce $2 billion the stock roared in response peaking at 125 before the pandemic and then the covid crash came and pfizer never bounced back climbing from the mid 70s to 96 today. they reported an okay quarter and expected sales but much better than expected cash flow and the company reinstated the forecast so the stock jumped 5% on the news. that's right these guys are delivering many of the same themes but the stock seams for 18 times so it's practically a value play for fintek he's the ceo of fiserv welcome back to "mad money." great to see you. >> great to see you. thanks for having me. >> i think people don't know the legend of frank. i'll say it. hold your ears so you don't get too big a heat you took over fiserv declining $2 billion in interest expense on the debt and

hawley: let me remind you of what the pfizer court said. the fbi's handling of the carter page applications was antithetical to the heightened duty of candor owed to the court. the frequency with ritz representations made by fbi personnel turned out to be unsupported or contradicted by information in their possession and with which they withheld information detrimental to their case, calls into question whether information contained in other f young applications is reliable. are you still look the view that these applications were not a close call at all and you would do the same thing now? these were appropriate steps? do you stand by that? miss yates: yes, senator. if you put my testimony in context, i was referring to the decision i made at the time. based on the factual information presented to me. sen. hawley: you for a passive party in this? you are telling us now, you did read the applications but you were also duped by the fbi and for that reason you signed off on misleading applications that a fisa court said were so bad and mislea

pfizer started just after moderna. it does not appear that pfizer is ahead of moderna. appears that this is sort of where we are. moderna -- pfizer says more than 2,000, moderna says about 4,500. >> all right. interesting, very interesting, especially given some of the promises or claims that have been made. the science here my make it very difficult at that pace. elizabeth, please keep us posted. >> that's right. >>> still ahead, the one country declaring victory over coronavirus lifting all of its restrictions. owning a business means owning a lot of uncertainty. but unknowns bring opportunity, too. like the chance to find new ways of doing business. we can help you set up an online store, with pickup, delivery, or shipping. and touch-free ways to take payments, too. we have all these tools, ready for when you need them. so even though we can't predict the future, we can help you be ready for whatever's next. see everything we can do at square.com. we can help you be ready for whatever's next. for bathroom odors that linger try febreze small spaces. just press firmly

which include things like chills headache muscle pain and fatigue now the next one then there is pfizer that's right now developing more than one vaccine when partnership with german company bio and tech now the most promising one is there be n.t. 16 to be to a vaccine and it's moving into a combined phase $2.00 and $3.00 also started last week so they're going into phase $2.00 and $3.00 together now if their trial is successful pfizer and bio and tech have said they're on track to seek a regulatory review as early as october and if they get an emergency authorization from the f.d.a. which is very likely the plan to have about a 100000000 doses by the end of the year and about $1.00 b.n. by the end of 2021 now those side effects with bad drugs are generally mild to moderate lasting about one or 2 days which also include fever for tb and chills now allow. lastly there is no over no over x. which is a maryland base bio company entering into phase 3 trials next month so in the fall and phase 2 trials have showed that the participants god the vaccine had levels of anti-bodies that can fight

of course the pfizer deal was for $19.50 per dose but pfizer didn't get any government funding and moderna had received almost $1 billion to support the development of this vaccine. the government has an option to purchase 400 million more doses and the company is saying the vaccine will be free to the american people. >> we know that j & j and astrazeneca have vowed not to make any money off the vaccine which is may be one reason they're priced lower than pfizer. >> pfizer, a very large company but not saying it's doing this not for profit. >> meg terrell g guy, what do you make of this vaccine news >> it's fascinating obviously. moderna was north of $90 i think given this move it's, what, 74.5 makes sense. what do i think of it? if you're looking to trade it, i wouldn't look at moderna i would look at gilead gilead has been weak for some time now $67.50 is a level where resistance many months ago resistance becomes support if there's weakness on this back of this, i'd rather buy gilead than chase moderna. >> if you have a vaccine, you may not have as much demand for some sort of treatmen

wasn't pfizer riding high on the vaccine?hat has amgen got how many divisions does amgen have >> it's weird. >> yeah. >> well, who knows anyway, it's a marketing tool for dow joneseven though they don't -- >> it is salesforce -- i bet you they do the greatest crm company and in the dow unlike oracle, you know, unlike google. whatever how about -- all right let's get to the heart of things, carl what the hell is walgreens doing in there what is that i mean, have you seen that stock? i mean, you want the dow to go down, you put a couple walgreens in there that's one of the worst. remember, walgreens was a partner of thernos and that was the hope >> we could do that all day, jim, playing the chess game of what belongs and what doesn't belong more importantly, jim, was yesterday the influence of convalescent plasma and vaccine hopes, today this phone call with lighthizer and mnuchin and the vice premiere reaffirming their commitment to phase one even though china has to pick up the face in terms of their commitment for purchases

en los estudios de moderna, de pfizer, estÁ en fase tres, donde se ve si la vacuna sirve o no.bemos si va a servir, en la personalmente, en base a lo que se, y en base a lo que estÁn brincando esa fase, no me pondrÍa esa vacuna. tienen que ser estudiadas, se estÁn brincando una fase fundamental del desarrollo de la vacuna,. carolina: aquÍ en estados unidos cÓmo van avanzando los ensayos clÍnicos en este país, han conseguido suficientes voluntarios ustedes? >> ahÍ vamos, yo estoy involucrado en el estudio de la vacuna de moderna, de los 30.000 participantes que se refieren, ya 5000 han ingresado, hacen falta 25.000, pero se estÁn consiguiendo voluntarios a la velocidad necesaria. nos gustarÍa que hubiera en mÁs voluntarios afroamericanos y tambiÉn hispanos, en lo personal tengo mucho interÉs que haya participaciÓn de los hispanos en ese estudio de vacuna, porque ha habido una afectaciÓn importante de esta enfermedad en los hispanos, requerimos saber si esta vacuna sirven hispanos. borja: doctor del rÍo, querÍamos tocar otro tema con usted, recientemente la actriz, alyssa milano,

todd: 19 after the hour, pfizer seeking approval for its coronavirus vaccine by october.n: we will ask doctor nichols have fire who joins us next. >> i took over the country who is covered on this front, convalescent plasma you saw, remdesivir, we will send vaccines pouring out years ahead of what they would have been. >> donald from celebrating the pharmaceutical establishment in the fight against covid-19 as pfizer confirms their vaccine is on track for regulatory review in october. medical contributor doctor nichols have fire, good to see you. what does this mean as far as the timeline goes, if something is up for regulatory review in october where are we with timing? >> we have several companies entering phase 2 and 3 of their clinical trials, pfizer being one of them. they said they would be up for regulatory review in october and what that means is we have their phase i data that shows this is safely administered and they are well on their way to phase 2 and 3, 11,000 participants have received the vaccination and are reporting 3.8 times higher antibody response tha

the firms pfizer and biontech are working on a vaccine candidate.he study covered 45eople from 18 to o 55. the researchers report that 21 days after vaccinatitions, antibodies for the coronavirus were detected in the blood of all those who got a shot. the researchers say more than half the trial subjects complained of a headache or other side effects but no serious health issues were recorded. the vaccine development is in the final phase. pfizer says the firms aim for approval as early as october. >>> meanwhile many countries are still fighting to contain the coronavirus. the french government is mobilizing the police to ensure people wear a face mask as the virus spreads again. some cities including paris and marseilles already require masks in commercial facilities and other indoor spaces. those who don't wear a face mask face a fine. >>> organizers of the paris marathon have canceled the event this year. it had been delayed from april to november due to the pandemic. >>> and washing hands with soap and water is one way to control the spread of t

so this also means that the ones trying to do 30,000, pfizer and moderna, might take longer than somee have hoped. so let's see how that's going. usncine: what can you tell about therapeutics? have we had any big developments, or are these the same drugs that were used a couple of weeks ago? sam: no new drug information. there is quite a lot being studied, and some specifically rather than repurposed. if you think about what we have already seen already with remdesivir, it has been repurposed, which is not a problem, but drugs specifically being tested in terms of treating the disease or antivirals, we are still waiting for some news on that, particularly people like pfizer and merck are doing some interesting work in that area. then you've got the immune system, which i think patrick vallance said this on that same podcast. a new system and a vial is therapeutic antibodies, antibodies that have been made so you can have a straight response to the virus. they seem to be having a tough time enrolling patients again. everyone is scrabbling for patients now. that is going to be an intere

tal y la otra mitad un placebo, este estudio de la vacuna relacionada con los laboratorios niños pfizerés) >> este estudio se lleva a cabo más rápido de lo normal de los procesos parecido, una dentarios deben ser de entre 18 a 25 años de edad se le dará la primera dosis después tendrán que hacerse un examen el cual serán monitoreados es necesario porque todo mundo ya cuatro meses que no trabaja >> pero los jóvenes están a favor porque afirman que muchas cosas que se desconocen sobre este virus >> honestamente tengo miedo que nos dice que estaba con aerostar a la altura >> la participación de los latinos es crucial >> si desea participar visite esta página >> con la salud no se juega >> la meta según pfizer es reclutar a muchas personas >> si todo marcha bien la vacuna puede estar disponible a principios de año coste de la universidad de san francisco desarrollaron un aerosol que contiene anticuerpo que ayudaría a frenar la propagación del coronavirus. el aerosol contiene anticuerpos provenientes de camellos y llamas se mantienen conectados a la molécula del virus por tiempo indefinido.

i feel bad for pfizer. what did they do wrong >> look, i understand we need to have more skploeexposure with a coming out of the dow with that coming down to 26% it was a huge chop getting more exposure. i was with you, i thought pfizer is coming out? this is still the way that world is powered >> how about the futures everything that could go wrong with china is going wrong with the dow. it's crazy good news is good news bad news we'll see. now china matters again. we'll get a little body language it is crazy. entering the tunnel -- >> we got to get a picture of you. nine years ago, you played "call me maybe." and had a little photo of me sitting on an empty chair. after the republican convention and clint eastwood did his empty chair routine. i came late. we'll have to get the music when you arrive >> it is fine. my hair. and i'm getting a hair cut today. >> there is a tease. tune in at 6:30 for joe's hair >> 6:20. >> we are going to lose you in the tunnel we'll see you in a few minutes let's take a look

>>> honeywell are in while exxon mobi mobile, pfizer and raytheon are out. the billionaire tilman fertitta will be here "power lunch" starts right now >>> the dow making major moves to keep up with the changing times and the changing economy bob is looking at the moves and how they will affect the markets. >> bob >> a bit of a shake up in the dow but the moves make some sense. let me explain why let's take it piece by piece first we have salesforce.com replacing exxon mobile the apple split has reduced the tech weighting in the dow and we need more technology sales force reflect the growing importance of software overall in the u.s. economy. you don't need two oil companies in the dow you don't need exxon and chevron with energy only 3% of the s&p one of them chevron will do. let's look at the dow industrials. pfizer is the lowest stock price in the dow the price would be even lower. another reason to move it away amgen is reflecting the growing importance of the biotech space. this sounds like two industrial swaps and they are theytheon overlaps a bit with

there is modest profit here, and that's both with what pfizer has said, right there at $20 a dose.y they are making some profit, and moderna as well make some profit. i think the bigger picture beyond the profits and the $30 billion market cap, is really about whether both for pfizer and beyondtech and moderna, are there other vaccines, other programs, other pipelines beyond it that we'll hear about if 100 million people took your drug -- >> uh-oh. >> i think we're having -- >> and i had a burning question. are we going to get him back there are so many companies that are developing vaccines right now. let's siem all of them come to market how do we side which vaccine -- how is that competition going to work >> how it's going to be distributed, i think, is a big question obviously there won't be enough vaccine produced to inoculate the entire population. but from an investor standpoint will this be money made year after year >> and very key is the international play as well our thank to michael yee of. >>> the gold run taking a breather a top technician seems something in the chart

it's not the big names that you and i would recognize like pfizer or johnson and johnson pfizer does have a little bit but not a lot. is actually these small very focused companies the focus on pain and then not names in the household names they don't have to worry as much about the sort of reputational damage as forces in our nation strengthen against the over prescribing of opioids from a suitable company see their us more could eventually narrowing. as one door closes another opens produce private company owners international from monday for money has already begun the same kind of marketing campaign in latin american asia the middle east and africa. nations where chronic pain is high and people haven't the money or access to medical treatment communities ill equipped to handle an opioid epidemic los angeles times reporter harriet ryan was the 1st to break the story interviewed someone who is going around the world training physicians in foreign countries for credit for teaching them how to use oxycontin he admitted he doesn't use it as a practice citizen think it's a. as big phar

to bring somewant breaking news to you from pfizer.cal giant saying that their vaccine which was withoped in conjunction the biotech company, saying that they are on track to seek an october regulatory review. that pfizer is seeing a supply of 1.3 billion doses by the end of 2021. they are looking to get that fda and other regulatory to review by october, saying the immunogenic to city in younger and older adults, and that it was well tolerated within that 11,000 participants. i am wondering though, given the vaccine race, how much are we seeing the markets really already pricing in? i've heard from analysts preiser -- prior to pfizer coming out saying an october regulatory review and even approval was likely. it does seem like the market is always one step ahead of its good news assumptions when it comes to the vaccine story. seeing ist we are that the progress that we can read in terms of a vaccine is something that the market is starting to take into account. we also have a sub quarter, which is going to show some sharp recovery. so

tremendous pfizer abuse. it was amazing that it has taken this long. it has been proven substantially, not only fisa abuse, but changing documents and putting documents in front of the fisa court and courts that are disgraceful that they could have done it. the fact is, we caught joe biden , president obama, the whole group, you can look at brennan and comey and klapper, the whole group, we caught them spying on our campaign. this was an illegal act like no other illegal act. this was treason. this was at the highest level of treason. and obama and biden got caught spying on my campaign, using intelligence agencies of the united states government to do it. both before and after the election. so before the election, then after i won they continued. it is totally illegal activity and we have to see what is happening but as far as kamala is concerned, she is a big tax raiser, she is a big slasher of funds for the military and she has got a lot of difficult things that she is going to have to explain. , one ofe was very nasty the reasons that surprised me,

pfizer signed a multiyear deal with gilyard siead sciences to remdesivir. and that is showing signs to help patients recover faster. gilead based in foster city is hoping to make enough remdesivir to treat 2 million patients by the end of the year. and pfizer is just the latest company to join the list that they are partnering with. the company is also working with bio entech to develop a vaccine. >>> and ever since the pandemic began, we've heard over and over we will turn a corner when there is a vaccine. so where are we when it comes to developing a vaccine? we hope that you will join us for a special series of stories exploring what role the bay area is playing to develop one. have the experiments under way shown any success and will people want to get a vaccine once it is approved? you came watch all this week on our app and our website. >>> coming bouing back from unemployment. how some laid off workers right here in the bay area turn their new free time into a business opportunity. >> afrnnd the deadline looming people struggling to pay the rent in a

in the x, raytheon, pfizer and exxonmobil there is very little indexed to the dow industrials average. over a trillion is indexed to the s&p, and that's the one that really matters >> bob, thank you. we'll have more on that in a little bit >>> meantime we have seen surprisingly strong economy lately including home sales. a setback to that positive story, consumer confidence came in much lower than expected. how much of a setback is it and what does it mean for the market let's bring in wasif latif and barry james at james investment research barry, i'll start with you is the drop is consumer confidence a warning sign as far as your concern about what lies ahead for the stock market >> it is a concern obviously the consumer is the largest part of our economy. if they're not confident in the future, then it will mean they pull back on spending and that will have a ripple effect. we're watching that very carefully. there are a lot of things going on in people's minds right now one of the good things for consumers, though, their finances are okay, their bankruptcy rates are heading down,

kathryn edwards is on pfizer's vaccine safety board.the five members of the committee video chat to carefully look through data for adverse effects, especially serious ones such as hospitalizations. >> we're very, very cautious in how we look at the data. certainly if there were a severe reaction, we would get that information right away. >> reporter: dr. edwards says there is no evidence so far the vaccine causes serious reactions but that mild reactions are common and should not deter anyone from getting vaccinated. >> you may have a sore arm, or you may have a little tenderness, or you may have a little headache, a little fever. so those are things to be expected. it's just your immune system getting tweaked, and you're making a better response. >> reporter: trial participats are required to self-monitor and log their symptoms on an app reporting their temperature and any reactions daily for a week after each injection. >> logging into my phone -- >> reporter: they will continue to log any symptoms on a weekly basis for two years. on

pfizere news on a vaccine serves as a tailwind. plus, biden vows to end the darkness. calling his opponent a national embarrassment. he promises to support the working class and reform taxation. look at the futures right now. in terms ofains tech stocks in the u.s.. a new high. now we see a little bit of a mixed picture with ftse futures pointing down, but continental futures are on the rise. back all gaining. let's take a look at what u.s. futures are showing us. more green arrows. almost 0.2 percent on nasdaq futures right now. alsond dow futures are gaining. what are you seeing on the gmm? anna: it seems that markets, investors taking a glass half-full approach. you can see some of those markets doing well on the screen right now with the south korean market up by 1.4%. coming through. there are some reasons to be cheerful. you mentioned the virus, latest news out of pfizer. also, the tech rally, factoring that in. if you need to read across from the u.s. into europe and asia, that is one reason for optimism. on the downside, that gloomy data on jobless claims from

the incident was a sad chapter in the history of vaccine manufacturing fast forward to today and pfizer is one of the pharmaceutical companies that has a covert 1000 vaccine in stage 3 human trials there's no guarantee it will be successful nevertheless the u.s. government has given the company hundreds of millions of dollars to speed up the development process in exchange if the pfizer vaccine turns out to be the one that works the u.s. government will control the rights to the 1st $100000000.00 doses the white house is pushing ahead so fast officials there claim they could have as much as 300000000 doses available by the end of this year in a program they're calling operation warp speed some back soon experts i spoke to said they hope that moving so fast doesn't lead to mishaps like what happened with the polio vaccine you don't actually want to back see. that is developed at will speed i mean really you know you were vetting that has developed as safely and key a fleet as any other boxing that you're comfortable putting in yourself or your child for now the race is on balancing speed

there is good news out of pfizer. good to see you as always. thank you. >>> developing this morning, a brand new report from the labor department on hiring and unemployment. that's due in just a matter of minutes. and that's interesting because, also due is some help for millions of americans. talks for the stimulus to help those hard-working americans who have lost their jobs in the pandemic, those talks are on the brink of collapse at this point. the white house and democrats in fact so far apart, it's not clear if they're even negotiating anymore. lets get the latest from cnn congressional reporter lauren fox and cnn political correspondent, abby phillips. where do things stand this morning. >> reporter: things are not in a good place. last night they met for about three hours but both sides walked out and had a lot of negative words to say. it was more of a blame game than it was a hopeful die tribe about getting a deal. and i will tell you up here on capitol hill this has been the momentum all week long. there have been nearly a dozen of t